Global COVID 19 Vaccine Market Overview
The SARS-Cov2 virus causes COVID-19, which is a pneumonic disease. SARS-CoV and MERS Virus were COVID-19's forefathers. The mutation in the genetic material of SARS-CoV2 was caused by the loss of a few base pairs. A COVID-19 pandemic has erupted around the world. WHO and collaborators are racing to create and deploy safe and effective vaccines as they work together on the response to monitor the pandemic, advise on crucial measures, and distribute essential medical resources to those in need. Every year, millions of lives are saved thanks to vaccines. Vaccines function by instructing and preparing the body's natural defences – the immune system – to identify and combat the viruses and bacteria they are designed to combat. If the body is later exposed to disease-causing germs after vaccination, the body is able to kill them right away, avoiding illness. Vaccines are an important new weapon in the fight against COVID-19, and the fact that so many vaccines are proving to be effective and are being developed is extremely promising. COVID-19 Vaccine Market is estimated to be US$ 25.85 billion by 2030 with a CAGR of 7.4% during the forecast period
Impact of Covid-19 pandemic on market
The need for specialised storage facilities with subzero temperatures for COVID-19 vaccines is seen as a major challenge in the COVID-19 vaccine supply chain. Many developing and developing countries lack the resources necessary to store and administer vaccines to patients. Improved storage and delivery system for COVID-19 vaccines is a top priority for vendors and governments around the world.
Global COVID 19 Vaccine Market Dynamics
Rising initiatives by government bodies
Government funding for vaccine production is expected to increase in the coming years, as is global organisations' participation in the development of appropriate vaccination facilities in endemic areas. Furthermore, during the forecast era, the high demand for coronavirus vaccine, ongoing government initiatives to procure the vaccine, and waves of infection are expected to drive market development. As healthcare authorities and governments try their hardest to vaccinate the population to prevent the spread of coronavirus disease, hospitals will gain a significant market share, followed by clinics, vaccination centres, and academic and research institutes.
Growth in business operations by emerging and small sized players
The market is being driven by the continuous and rapid increase in the number of COVID-19 cases among people, its prevalence, and the increase in the mortality rate of patients around the world. As a way to stop the spread of COVID-19 cases worldwide, several vendors are focused on developing and commercialising new vaccines such as mRNA-based, DNA-based, attenuated, protein-based, and antigen presenting cell vaccines. Around 30% of the COVID-19 vaccine pipeline is made up of protein-based vaccines. Since mRNA vaccines do not interfere with human genetic material, they have no side effects or toxicity, and there are no virus particles in the vaccine. These are also main drivers of the global COVID-19 vaccine market.
Global COVID 19 Vaccine Market Segmentation
The covid-19 Vaccine market is segmented based on product, technology, patient and End-user.
On the basis of product, the global covid-19 vaccine market is segmented into Monovalent vaccine, Multivalent vaccine. Based on technology,, the target market is segmented into Nucleic acid-based, Vector based, protein based, and whole virus . On the basis of patient, the target market is segmented into adult, Paediatric, and Senior citizens. On the basis of End-user, the global covid-19 vaccine market is segmented into vaccination centers, clinics, hospitals, research institute, academic and others.
Regional Insights:
On region the Covid-19 Vaccine market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The COVID-19 vaccine market is dominated by North America, which is followed by Europe. The rising number of COVID-19 cases and their rising prevalence among patients in North America, technological advances accompanied by increased government support for R&D activities, and large corporations investing heavily in COVID-19 diagnostics are all factors that have contributed to North America claiming a significant share of the regional market.
Report Scope:
Attribute |
Details |
Base year for estimation |
2020 |
Forecast period |
2020 – 2030 |
Market representation |
Revenue in USD Million & CAGR from 2020 – 2029 |
Market Segmentation |
By Product- Monovalent vaccine and Multivalent vaccine By technology–Nucleic acid-based, Vector based, Protein based, and Whole virus By patient–Adult, Paediatric, and Senior citizens By End-user- vaccination centers, clinics, hospitals, research institute, academic and others |
Regional scope |
North America - U.S., Canada Europe - UK, Germany, Spain, France, Italy, Switzerland, Russia, Rest of Europe Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific Latin America - Brazil, Mexico, Argentina, Rest of Latin America Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa |
Report coverage |
Revenue forecast, company share, competitive landscape, growth factors, and trends |
Segments Covered in the Report:
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2019 to 2030. For the purpose of this study, has segmented the global covid-19 vaccine market report based on product, technology, patient and end-user.
Covid-19 Sample Collection Kits Market, By Region:
- North America
- Middle East & Africa
-
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
-
- Latin America
-
- Brazil
- Mexico
- Rest of Latin America
-
- Asia Pacific
-
- China
- India
- Japan
- South Korea
- Rest of Asia Pacific
-
- Europe
-
- Germany
- Russia
- France
- Switzerland
- United kingdom
-
-
- U.S.
- Canada
- Middle East & Africa
Global COVID 19 Vaccine Market Key Players
The key players operating in the Covid-19 Vaccine Market include Astellas Pharma Inc., Daiichi Sankyo Company Ltd., Abbott Laboratories, CSL Ltd., GlaxoSmithKline plc, Moderna Inc., BioNTech SE, Novavax Inc., Johnson & Johnson, and AstraZeneca plc., Bharat Biotech, Pfizer, CureVac, SinoVac, Sinopharm. These industry behemoths are forming alliances and forming collaborations to increase their production capacity and profit margins in order to meet rising demand.
Global COVID 19 Vaccine Market Key Issues Addressed
- In June 2024, AstraZeneca responds to Covishield vaccine concerns. In response to growing concerns surrounding potential side effects linked to the AstraZeneca-Oxford Covid-19 vaccine, the pharmaceutical giant restated its dedication to patient safety. This announcement followed acknowledgements that the vaccine, known as Covishield in India and produced by the Serum Institute of India, can lead to rare instances of blood clots and low platelet counts
- In March 2024, New India' invents Covid vaccines, lands near South Pole of Moon: Jaishankar. Union Minister S Jaishankar highlights India's transformation towards self-reliance with the vision of "Atmanirbhar Bharat." Emphasizing the shift in mindset, he discusses India's response to global challenges through initiatives like Make in India, fostering creativity, innovation, and intellectual property rights. The minister asserts India's achievements in 5G, COVID vaccine production, and lunar exploration, highlighting the nation's rising trajectory in global innovation.
- In January 2024, New U of A-based study to examine very rare adverse events linked to COVID-19 vaccines. A University of Alberta professor is co-leading a new international vaccine safety network to examine why some people who received a COVID-19 vaccine experienced very rare adverse events associated with the vaccine.
Global COVID 19 Vaccine Market Company Profile
- Astellas Pharma Inc.,
- Daiichi Sankyo Company Ltd.,
- Abbott Laboratories,
- CSL Ltd.,
- GlaxoSmithKline plc,
- Moderna Inc.,
- BioNTech SE,
- Novavax Inc.,
- Johnson & Johnson,
- AstraZeneca plc.,
- Bharat Biotech,
- Pfizer
- CureVac
- SinoVac
- Sinopharm
“*” marked represents similar segmentation in other categories in the respective section
FAQs
The global covid-19 vaccine market is segmented based on product, technology, patient, and end-user.
Since mRNA vaccines do not interfere with human genetic material, they have no side effects or toxicity, and there are no virus particles in the vaccine. These are also main drivers of the global COVID-19 vaccine market.
Europe is expected to lead the market and estimate for about 35% revenue share in 2020. The COVID-19 vaccine market is dominated by North America, which is followed by Europe.
The industry behemoths are forming alliances and forming collaborations to increase their production capacity and profit margins in order to meet rising demand.